Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 9/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358084 | 0.73 | MAPK1 (0.38) | GRM4ITK | |
| SCHEMBL12433139 | 0.73 | PIM1 (0.55) | PIM1 | |
| SCHEMBL16256476 | 0.68 | PRKCQ (0.58) | PIM1 | |
| SCHEMBL30492599 | 0.66 | CYP3A4 (0.50) | JAK2IDH1 | |
| SCHEMBL1071454 | 0.66 | CYP3A4 (0.50) | JAK2IDH1 | |
| SCHEMBL4143459 | 0.66 | MAPK9 (0.49) | GRM4ITK | |
| SCHEMBL14906031 | 0.64 | GRM4 (0.71) | GRM4PIM1 | |
| SCHEMBL24809485 | 0.64 | TGFBR1 (0.40) | JAK2IDH1TGFBR1ITK | |
| SCHEMBL19801401 | 0.63 | GRM4 (0.33) | GRM4 | |
| SCHEMBL29727933 | 0.63 | KDM4E (0.71) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895740-B2 | Pyrazolopyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895740-B2 | Pyrazolopyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895740-B2 | Pyrazolopyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130053388-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053388-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053388-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-28 | — | — | US | disclosed |
| EP-2550272-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011094288-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011094288-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053388-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | MAP3K5, MAP3K2, MAP3K20 | JAK2 159/4885GRM4 3473/4885NR1H4 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.